Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 5, 2011, Pages 701-712

  Tack, Jan ^a   Janssen, Pieter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

acotiamide; functional dyspepsia; gastric accommodation; gastric emptying; postprandial distress syndrome

Indexed keywords

ACOTIAMIDE; PLACEBO;

CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; TREATMENT RESPONSE;

ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DYSPEPSIA; GASTRIC EMPTYING; HUMANS; STOMACH; THIAZOLES;

EID: 79953668479     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.562890     Document Type: Review

References (31)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466-79
2. Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8(6):498-503
3. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-55 (Pubitemid 39345892)
4. Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 2008:57(12):1666-76
5. Karamanolis G, Tack J. Promotility medications - now and in the future. Dig Dis 2006;24(3-4):297-307 (Pubitemid 44114423)
6. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8(6):690-6
7. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;18(4):CD001960
8. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebocontrolled trial. Aliment Pharmacol Ther 2000;14:1653-61 (Pubitemid 32011739)
9. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008;57:740-6 (Pubitemid 351716964)
10. Vakil N, Talley NJ, Zakko S, et al. Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials. Am J Gastroenterol 2008;103(8):1906-19
11. Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000;294:33-7 (Pubitemid 30434667)
12. Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000;36:69-81
13. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effect of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol 2004;505:31-5 (Pubitemid 39535673)
14. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride and mosapride. Submitted for publication, 2010
15. Di Stefano M, Vos R, Klersy C, et al. Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Am J Gastroenterol 2006;101(12):2797-804 (Pubitemid 44902653)
16. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-91 (Pubitemid 44893562)
17. Oliver SD, Ward C, Ward J, et al. Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Abstracts of the Joint Meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR - Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2000. p. 244
18. Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20:1051-9
19. Adam B, Liebregts T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia: a double-blind, randomized, placebo controlled crossover study [abstract]. Gastroenterology 2009;136:A535
20. Kusunoki H, Haruma K, Imamura H, et al. Therapeutic efficacy of Z-338 (Acotiamide Hydrochloride) in patients with functional dyspepsia is based on enhanced post-prandial gastric accommodation and emptying: confirmed by real-time ultrasonography. Gastroenterology 2010;138(5 Suppl 1):S154-5
21. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21(3):272-80
22. Matsueda K, Hongo M, Sasaki D, et al. Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology 2005;128:A467
23. Talley NJ, Tack J, Kowalski D, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial [abstract]. Gastroenterology 2008;134:A-157
24. Tack J, Talley NJ, Kowalski D, et al. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dispepsia [abstract]. Gastroenteroloy 2008;134:A143
25. Tack J, Caenepeel P, Piessevaux H, et al. Assessment of meal-induced gastric accommodation by a satiety drinking test in health and in functional dyspepsia. Gut 2003;52:1271-7 (Pubitemid 37026458)
26. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173
27. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999;45(Suppl 2):II37-42
28. Available from: http://www.zeria.co.jp/english/pdf/press20090303.pdf
29. Available from: http://www.zeria.co.jp/english/pdf/press20100628.pdf
30. Available from: http://www.zeria.co.jp/english/pdf/press20100929.pdf
31. Parkman HP, Trate DM, Knight LC, et al. Cholinergic effects on human gastric motility. Gut 1999;45(3):346-54 (Pubitemid 29400709)